Á¦  ¸ñ :   IPT(Àν¶¸°Áõ°­¿ä¹ý) @@@ IPT Protocol  ###GENERAL PREAMBLE: There are three characteristics of IPT which distinguish it from conventional medical management: - 1) the intravenous administration of a dose of regular insulin, followed by an intravenous infusion of a prepared glucose solution. Through the judicious use of these, a mild hypoglycemic state is temporarily created, and then abolished; 2) the administration of other drugs (called Primary Medications) specifically targeted to treat the patient's particular diagnosed disease. These drugs are administered at the time of the glucose nadir produced by the insulin injection (approximately 30 minutes after). 3) Holistic perspective: This involves the administration to the patient of certain other allopathic drugs and combinations of nutritional supplements (called Secondary Medications). These are given as that part of an IPT treatment which treats the whole person with their disease, rather than just treating a disease which is seen to be afflicting the body of an otherwise completely healthy person. Products here include aids for the proper functioning of the gastrointestinal, respiratory, immune and excretory systems. Particular emphasis is always given to the patient's liver function. Both the Primary and the Secondary medications are administered - either orally, intramuscularly, and/or intravenously, according to the therapeutic agent's presentation - as described below in THERAPEUTIC MOMENT. Insulin Potentiation Therapy was developed in Mexico City over 65 years ago by Dr. Donato Perez Garcia. The present study will attempt to replicate the clinical results reported from his practice of medicine - of Dr. Donato Perez Garcia himself, and that of his son and of his grandson - doctors all, and all of the same namesake. Therefore, in order to attempt this replication, complete adherence to the extant clinical practice of IPT in Mexico is integral to the performance of this study. The drugs and their doses will be the same as prescribed abroad - inasmuch as this is possible given the differences between the Mexican and the American pharmacopoeias. ###Introduction to the IPT Protocol --Insulin Potentiation Therapy (IPT) is a medical protocol in which the hormone insulin is used as a pharmacologic adjunct to potentiate the effects of commonly used allopathic medications. The usual starting dose of insulin used in this study is 0.4 units/kg. ### Patient Admission Procedures ---Patients should present in a FASTING STATE on the day appointed for their IPT treatment. If the treatment is scheduled for the morning hours(before noon), patients should take no food by mouth after 10:00 PM on the night before their scheduled treatment. Drinking water is OK; it is encouraged to maintain a good state of hydration (see below). If treatments are scheduled for the afternoon, a light breakfast (a serving of fruit, a piece toast, and 4 ounces of juice) may be eaten before 8:00 AM, with nothing by mouth - except water - thereafter. ---It is important that the patient be advised to maintain a good level of hydration while taking IPT treatments. Any chemotherapy regimen using the kinds of drugs applied in IPT treatments will require patients to be well-hydrated so as to ensure the minimum in side-effects from the chemotherapy drugs. This is particularly important for regimens including cyclophosphamide, methotrexate and cisplatin. For the treatment of diseases other than cancer, such as chronic infections & etc., this issue of good hydration is not necessarily as relevant, however, it is sound practice to be well-hydrated in any event. ---On admission to the treating facility the day of the treatment, the vital signs are taken and recorded. An intravenous line is also started at this time in a peripheral vein, and 500 ml of normal saline solution is infused through this initially at a 'keep vein open' rate (approx. 50 ml/hr). During the period of close observation following the insulin administration, the vital signs are measured and readings are recorded. Taking vital signs is done once before the treatment - before administering the insulin - once again at the THERAPEUTIC MOMENT, and a final time after completion of the treatment. Blood glucose determinations (by finger stick method) are similarly done at these three points during IPT treatments. ### Administration of Insulin ---The usual starting dose of insulin (Humalog - Lilly) that is given is 0.4 unit/kg body weight. This is administered intravenously to the subject, and the time is charted. Education about insulin's effects is repeated, describing and underscoring the importance of the symptoms of hypoglycemia, and the importance of communicating clearly about what is experienced. As stated above, glucose determinations will be done by finger stick at three times during the treatment: once before administration of the insulin; another at the THERAPEUTIC MOMENT; and one final time at the end of the procedure. As well as actually measuring the blood glucose, clinical monitoring of patients' responses to the administered insulin - with experience - becomes a reliable method of determining the time of the THERAPEUTIC MOMENT. ### Administration of Oral Medications ---All prescribed oral medications (primary or secondary) for study subjects in the IPT treatment are administered at the time of the insulin administration - just following it. These are taken with sips of water. This assures that these medications will be absorbed into the blood stream by the time of the THERAPEUTIC MOMENT. ### Administration of Intramuscular Medications ---All prescribed intramuscular medications (primary or secondary) for study subjects in the IPT treatment will be administered ten to fifteen minutes after the time of the insulin administration. These are given in the upper outer quadrant of the buttock, and the area is firmly massaged after their administration. This practice assures that these medications will be absorbed into the blood stream by the time of the THERAPEUTIC MOMENT. *** Following approximately 30 minutes of close observation after giving the insulin, another blood sample is drawn to determine the lowest blood glucose level that exists at this time. AccuChecks from a finger stick sample are the acceptable method of measuring blood glucose during IPT treatments. In the ideal situation, at this time subjects will be experiencing a feeling of inner warmth, sweating, and some dizziness as described in the following section on Symptoms of Hypoglycemia. The prescribed anticancer/other medications are now administered intravenously. The medications are given by IV push at a moderate rate via the injection port on the IV tubing. The tubing is crimped off above the injection port during the injection to prevent any back-flow of the medication up the IV line. After one medication has been administered, the IV line is opened fully and allowed to run freely for a few seconds to flush the medication out of the IV tubing and into the vein. This effectively prevents any drug-drug incompatibilities from occurring with the mixture of two successively administered intravenous drug products. All the IV medications are administered in this fashion. Following administration of the medications, 20 ml of 50% dextrose injection USP is injected into the bag of normal saline solution, and this is then allowed to run in at a wide-open rate (over 15 to 20 minutes). Alternatively, the 20 ml of 50% dextrose injection USP may be administered directly intravenously (see the following section on Management of Ideal Hypoglycemic Reactions). The final step in the procedure is having the subject drink a 12 oz. quantity of Gatorade. Not only does this provide supplementary glucose, along with a source of potassium, but it is appreciated by subjects at this stage of their treatment. They have been fasting, the hypoglycemia accentuates their hunger by this stage of the proceedings, and drinking the Gatorade becomes a much welcomed treat to herald the end of the treatment process. ### Observation Phase ---The subject rests under close observation in the treatment facility for another hour following the running in of the normal saline solution with the added 50% dextrose injection USP. Subjects are permitted to take additional Gatorade during the observation phase if they wish. Blood for a final glucose determination is taken approximately one-half hour after the IV solution has run in completely. Subjects are educated and instructed to report any symptoms of hypoglycemia to the medical and nursing staff. Should any hypoglycemic symptomatology recur during the observation phase, these are effectively managed by simply increasing the oral ingestion of sugar. Such reoccurring hypoglycemic events are not uncommon at this time during an IPT treatment, and they usually consist of only very mild adrenergic symptoms (sweating, tachycardia/fast heart rate). "Adrenergic" symptoms are those symptoms caused by reaction of the adrenal glands to the hypoglycemia. ---Uncommonly, subjects may experience more profound hypoglycemic symptoms during the observation phase, with the experience of some neuroglycopenic as described below. "Neuroglycopenic" symptoms are symptoms due to low blood glucose effects on the brain. In this event, subjects are given an additional amount of 25 ml of 50% dextrose injection USP intravenously, plus an additional 25 ml of 50% dextrose injection USP is added to another 500 ml of normal saline solution, which is run in at the wide-open rate. These late occurring hypoglycemic events do not constitute "excessive" reactions, and are not an indication to alter insulin dosing at subsequent IPT treatments. As a rule, consideration of reducing the dose of insulin only arises when there are the non-ideal insulin-associated events occurring at the THERAPEUTIC MOMENT (when the glucose concentration is supposed to be at its desired low level). ###Oral Medications on Non-Treatment Days ---"Non-treatment" days are defined as those days when subjects are not scheduled to receive an IPT treatment with insulin and the parenteral (IM or IV) anticancer drugs. On these days, most subjects being treated for cancer will be prescribed an oral form of anticancer medication - cyclophosphamide - to be taken either 50 mg or 100 mg daily. A number of other prescription or non-prescription preparations may also be prescribed - particularly products to help with digestion, elimination, and to promote healthy liver function. Particular attention to daily bowel function, and advice about how to maintain this is provided to patients taking IPT treatments. Routine ingestion of other prescribed medications, such as antibiotics, blood pressure pills, & etc., continues as usual. ###Frequency/Scheduling of IPT Treatment ---The scheduling of IPT treatments varies with the nature and severity of the diseases being treated. Generally speaking, IPT treatments are administered twice weekly for three weeks, and then weekly thereafter for periods of time determined by the extent of patient's clinical responses, and the overall goals of therapy. ###NOTES ABOUT THE USE OF INSULIN IN IPT TREATMENTS ***Administration of Insulin and Management of Hypoglycemia ***Insulin Dose Range ---The dose range for insulin administered in an IPT treatment is 0.2 to 0.4 U/kg body weight, intravenously, with the usual dose according to the clinical experience in Mexico being 0.4 U/kg. A discussion of procedures for titrating study subjects' insulin dose up or down, as needed, follows below in Titration of Insulin Dose. Typically, with the appropriate dose for a particular individual, the glucose nadir and its attendant ideal hypoglycemic reaction will appear approximately 25 to 30 minutes after the insulin injection. Glucose monitoring by finger stick/glucometer may be done at the bedside, however this is not a reliable way of determining optimal subject reaction to their insulin dose. Determination of the appropriate dose of insulin for individual study subjects is to be made on the basis of the clinically evident symptoms of hypoglycemia. More often than not, there is a direct correspondence between the measured blood glucose levels and the symptoms of hypoglycemia. However this is not always the case. Symptomatic hypoglycemia of a moderate degree is the desired result produced in IPT treatments. ***Symptoms of Hypoglycemia --- It is important for study subjects to be completely conversant with the range of hypoglycemic symptoms, and to be able to communicate their experiences clearly to supervising medical/nursing personnel. The nature of an insulin-induced hypoglycemic reaction described in the literature includes symptoms of hunger, thirst, diaphoresis, palpitations/tachycardia, trembling, and a nonspecific sense of arousal and/or anxiety. Some have described this latter experience as one of a sense of impending doom. The ideal hypoglycemic reaction experienced in a typical IPT treatment is more benign. Initially subjects will respond in the affirmative to the question, "Are you feeling any warmth" This is the most commonly seen initial manifestation of insulin's effect. The clinical experience indicates that the clinician can comfortably anticipate further patient symptoms of sweating, and an experience described as "dizziness" to appear five to ten minutes after the appearance of this feeling of warmth. With the appearance of this symptom (warmth), steps are then taken to proceed with the intravenous administration of medications and the hypertonic glucose (see the Therapeutic Moment, above). It is important for patients and supervising medical/nursing personnel to share a common understanding about these hypoglycemic symptoms, what it feels like to experience them, and to maintain a good level of communication at all times about them through appropriate questioning. ---The textbook symptoms of hypoglycemia described above are primarily the direct or indirect consequences of a sympathoadrenal response caused by the body's reaction to acute hypoglycemia on the part of the patient's adrenal glands. These symptoms are the adrenergic manifestations of hypoglycemia, and these adrenergic symptoms are considered acceptable in IPT treatments - although, typically, the only symptoms customarily experienced in a treatment are the feelings of warmth, some sweating, and a mild experience of "dizziness." ---There is another group of hypoglycemic symptoms, called neuroglycopenic symptoms, which are not routinely acceptable in study subjects undergoing an IPT treatment. These symptoms proceed along a spectrum from subtle impairments of mentation, visual symptoms (blurred vision & diplopia), impaired performance of routine tasks, confusion and disorientation, and then progressing on to the extremes of convulsions, and coma. Left to run on without any form of medical supervision or intervention whatsoever, severe hypoglycemia may lead to death. Study subjects who experience any of these neuroglycopenic symptoms during the time lines established for what is normally to be expected (25 to 30 minutes, warmth, sweating dizziness) are considered to have had an excessive hypoglycemic reaction to their administered insulin dose. The management of such occurrences is described in detail below in Insulin: Human Toxicology. ***Titration of Insulin Dose ---Subjects' reactions to the initial 0.4 units/kg insulin injection may be characterized as ideal, excessive, or poor. Ideal reactions are as described above in Symptoms of Hypoglycemia. No further dose titration for insulin is required in such subjects. Excessive hypoglycemic reactions have also been described in Symptoms of Hypoglycemia. The occurrence of an excessive reaction in considered a toxic event, and the management of this is thus detailed below in Insulin: Human Toxicology/Management. ---A poor hypoglycemic reaction is one wherein the study subject experiences little if any of the adrenergic symptoms of hypoglycemia after an elapsed time of 45 minutes to an hour following the 0.4 units/kg insulin injection. In such cases, the anticancer drugs are administered at this time, and the normal saline solution is allowed to run in at the wide-open rate as described below in Management of Ideal Hypoglycemic Reactions. No supplementary 50% dextrose injection USP is administered to the subject. At this time, these subjects are allowed oral intake of a sweetened, electrolyte containing solution - such as Gatorade. At subsequent treatments, such patients should have their insulin dosages increased by increments of 0.05 U/kg per treatment until they react in the expected ideal fashion. ***Management of Ideal Hypoglycemic Reactions ---The management of that degree of hypoglycemia occurring in the ideal treatment situation with the 0.4 units/kg insulin injection proceeds as follows. First, subjects have their anticancer medications administered intravenously as per directions in THERAPEUTIC MOMENT. These are given through the injection port on the IV line delivering the 500 ml of normal saline solution which has been running in at a "keep-vein-open" rate (see Patient Procedures on Admission). ---Following administration of the anticancer drugs, a 20 ml quantity of 50% dextrose injection USP is added to the normal saline solution, injected directly into the IV bag through the injection port provided for additives. Also, a quantity of vitamin C solution is injected into the IV bag. This prepared glucose/vitamin C solution is then allowed to run in rapidly at a wide-open rate (15 to 20 minutes). At this time, subjects are also given a 12 oz. bottle of Gatorade to drink. This provides a supplemental source of glucose as well as potassium. Potassium is driven intracellularly by insulin, and the resultant hypokalemia can rarely cause some muscle cramping. "Hypokalemia" means lok levels of potassium in the blood. The Gatorade effectively prevents this side-effect in the vast majority of cases. ---Experience has shown that the above described rate of IV glucose administration is sufficient to abort the hypoglycemic effect of the insulin. At the discretion of the treating physician, the aforementioned 20 ml quantity of 50% dextrose injection USP may be administered directly as an IV injection rather than running it in as an additive to the normal saline solution in the patient's IV bag. The circumstances that would encourage this decision would be complaints or the appearance in the patient of confusion & etc. The preferred practice of administering the glucose via the IV bag is that it avoids possible problems of thrombophlebitis - which can occur with direct IV administration of 50% dextrose injection USP. "Thrombophlebitis" is an infection or irritation in the vein that can sometimes cause the vein to become blocked by a small clot. ###Human Toxicology/Management of Excessive Reactions ---Toxic reactions to insulin include hypokalemia with muscle cramping, allergic reactions and excessive hypoglycemic reactions. Allergic reactions may be of two types: 1) a localized irritation at the injection site, and 2) a systemic reaction with generalized urticaria (swelling), dyspnea (shortness of breath), and wheezing, which may progress to anaphylaxis (a state of allergic shock). With the use of Humalog - insulin lispro injection [recombinant DNA origin] (Lilly), an allergic reaction would be a rare event. Should one occur, appropriate symptomatic or resuscitative measures should be undertaken, according to the demands of the situation. Subjects experiencing an allergic reaction to Humalog should be given an alternative insulin preparation at subsequent treatments, after appropriate skin testing to assure tolerance. Management/prophylaxis of the hypokalemia and muscle cramps is accomplished with an oral 12 oz. Gatorade drink. Rarely persistence of muscle cramping may require supplemental IV potassium administration. ---Hypoglycemic reactions of a mild degree are a normal accompaniment of IPT treatments. Excessive hypoglycemic reactions are characterized by the more rapid onset of the adrenergic hypoglycemic symptoms, and by the appearance of neuroglycopenic symptoms, such as disorientation and/or confusion. These latter are the signal events of a unacceptable of excessive hypoglycemic reaction in an IPT treatment. As soon as it is observed that a study subject may be experiencing an excessive insulin reaction, the subject should receive the administration of 25 ml of 50% dextrose injection USP intravenously. After normal conscious orientation of the subject has thus been reestablished, the other treatment medications may be administered according to the prescribed procedures. Following administration of these other treatment medications, 20 ml of 50% dextrose injection USP is added to the normal saline solution - along with the vitamin C - and this is then run in at the wide-open rate, as in the normal circumstance. ---Subjects experiencing excessive insulin reactions to the usual initial 0.4 units/kg insulin dose should receive 0.15 U/kg of insulin at their next treatment. Depending on the reaction to it, this dosage level may then be maintained or either increased or decreased - in 0.05 U/kg per treatment increments - until the expected ideal hypoglycemic reaction is produced. ---Subjects who are otherwise healthy and well-nourished will, in the vast majority of cases, react in the typical ideal fashion with their IPT treatments. All in all, the treatment procedure is commonly a most benign one. It may be anticipated that certain patients who are significantly ill with their disease, particularly those experiencing anorexia, may not have adequate liver glycogen reserves to be able to compensate in the normal fashion to the insulin administration. This may occasion an excessive hypoglycemic reaction. At the discretion of the clinician, such subjects may be started off in their course of IPT treatments at lower insulin doses (0.2 or 0.3 units/kg) to observe for their reactions. Adjustments in the insulin dose may thereafter be made according to the clinical response, and the guidelines given above. @@@ Insulin Potentiation Therapy for Cancer 3°¡Áö The conventional treatment for cancer is the familiar trio of chemotherapy, radiation, and surgeryÀÇ 3°¡ÁöÇ׾Ͽä¹ýÀÇ ´ÜÁ¡ÀÎ ¸é¿ªÃ¼°è ¼Õ»ó, ½ÉÀå-°£ µîÀÇ Àå±â ¼Õ»ó, »îÀÇ Áú ÀúÇϸ¦ ÇØ°áÇÏ´Â ¼ö´Ü À¸·Î °í·Á ***The Elka Best Cancer Foundation: IPT(Àν¶¸°Áõ°­¿ä¹ý) or IPTLD(Insulin Potentiation Targeted Low Dose ¾Ï¼¼Æ÷Ç¥Àû Àú¿ë·®Àν¶¸°Áõ°­¿ä¹ý-2009 ÀÌÈÄ) ---IPTLD¢â is the name chosen by Annie Brandt and the Board of Directors of the Best Answer for Cancer Foundation to more accurately describe the therapy. Same therapy, slightly different name to better express the concept.  In conventional treatment, chemotherapy drugs must be administered in doses high enough to kill a large number of cancer cells without killing the body's immune system and intestinal tract. It's a balancing act. Patients are given as much chemotherapy as their body can tolerate. It is like killing flies with a cannonball instead of fly swatter. You get rid of some flies, yes, but you have a lot of collateral damage. Good cells die along with the bad. Over time (and sometimes a fairly short period of time, days rather than weeks), this massive bombardment can lead to poor blood counts, organ failure, and death. Because an already poorly functioning immune system is subjected to radiation and toxic drugs, it is difficult to deliver a "cure."[1] ---A time-tested, modified form of chemotherapy has been used successfully and safely around the world for more than 70 years. It is called IPT, or Insulin Potentiation Therapy. Some people call it IPTLD, or Insulin Potentiation Targeted Low Dose therapy. ---IPT uses about one-tenth the dosage of a conventional chemotherapy regime. IPT provides a safer, much gentler alternative to conventional chemotherapy, without the harsh side effects. When combined with complementary therapies to nurture the body, it is also more effective. It is a smart way to approach cancer based on what makes cancer cells vulnerable. ###Sugar and Cancer ---There is a key difference between cancer cells and healthy cells: cancer cells run exclusively on sugar. Cancer cells have a ravenous need to consume the glucose (sugar) found in the blood stream. Glucose is their unique source of energy, and because of the relatively inefficient way cancer cells burn this fuel, they use up a great deal of it. This is why cancer patients lose so much weight. Because cancer cells require so much glucose, they virtually steal it away from the body's normal cells, thus starving them. ---To help sugar get inside the cancer cells, they are equipped with 10-16 times as many insulin receptors as healthy cells. Insulin manages the delivery of glucose across cell membranes into the cells. Put another way, insulin escorts glucose through the cell membrane, into the interior where the glucose provides energy to keep the cell alive. ---If you have had a PET scan, you have seen this connection between sugar and cancer cells at work. A PET scan is performed by injecting a radioactive agent and glucose into a vein. The cancer cells, always ravenous for sugar, take up the glucose much faster than healthy cells. The radioactive agent gets into the cell along with the glucose. Bingo – the scan produces a three-dimensional picture of a cancerous mass. ###Targeted Therapy Now, what would happen if, in addition to glucose, you add a little bit of chemotherapy to the mixture Bingo – the chemotherapy drugs are taken up into the cancer cells. The healthy cells are not bombarded. This is why patients undergoing IPT do not experience the severe side effects of conventional therapy. Generally, IPT patients do not go bald, nor do they experience severe nausea or organ damage. ###IPT uses only 10 - 15% of the amount of drugs ---The word "potentiate" means to make stronger or more effective. In this case, it means that insulin makes the chemotherapy more effective. A 1981 study conducted at George Washington University showed that when the chemotherapy drug, methotrexate, is combined with insulin, the drug's cell-killing effect increased by a factor of 10,000. Because insulin enhances the effectiveness of the drugs, IPT uses only 10% - 15% of standard dose drugs. There is no need to overwhelm a patient with large quantities of drugs in the hope that the drugs will kill the cancer before they kill the patient's immune system. ---There is a second way that insulin helps us defeat cancer. Insulin stimulates cells to grow, which they do by dividing. Cancer cells are most vulnerable to many chemotherapeutic agents when they are dividing.[2] With IPT, we use insulin's stimulating properties to catch more cancer cells in the process of dividing, so more of the drugs are absorbed than if division had not been encouraged. ---A third way insulin helps is with detoxification. Insulin increases "cellular permeability." Glucose goes in easier, and the low dose chemo goes in easier. The door swings both ways - toxins and debris from dying tumor cells also pass out much easier. Insulin facilitates the detoxification so necessary with cancer. ###Complementary Therapies ---There is universal agreement that cancer is a failure of the immune system. We feel strongly that "killing the cancer" is only one part of the job. Re-training and strengthening the immune system is another part of our job. Our patients continue to thrive and often end up with a healthier immune system than when they started treatment. ---We use complementary therapies to create a hostile inner terrain for cancer, to nourish the body and protect the organs, and to create a more robust immune system. ---As a tumor grows, the body may acclimate to the presence of abnormal cell growth, fooling the brain into accepting the cancer as a normal presence in the system. After the tumor is removed, the body may still respond as if it should be there, much like an amputee's "phantom limb" syndrome. One school of thought is that the brain sends messages that support re-growth. Acupuncture has been used successfully to retrain the body's immune system to defeat cancer, and correct or erase faulty body signals conducive to cancer.[3] ###Dr. Otto Warburg's description of the environment of the cancer cell: ---A normal healthy cell undergoes an adverse change when it can no longer take in oxygen to convert glucose into energy. In the absence of oxygen, the cell reverts to a primal nutritional program to nourish itself by converting glucose through the process of fermentation. The lactic acid produced by fermentation lowers the cell pH and destroys the ability of DNA and RNA to control cell division. Cancer cells then begin to multiply without restraint. Hyperbaric oxygen, for example, defeats cancer on a fundamental level. Some 75 years ago, Dr. Otto Warburg was awarded two Nobel prizes for demonstrating that cancer occurs when cells weaken due to lack of oxygen. According to Dr. Warburg, that weakness causes the environment to become more acidic – a perfect environment for the growth of pathogens and cancer. When we increase the amount of oxygen in the tissues by using a hyperbaric oxygen chamber, we make the environment inside our bodies much less friendly to cancer cells. Advanced cancer patients can be 1000 times more acidic than a healthy person. One way to make low-dose chemotherapy more effective is to insure that cancer cells are adequately oxygenated and not acidic. ---Infrared saunas are another fundamental approach to defeat cancer through the use of elevated body temperature. When fighting pathogens, the body sometimes creates a fever to raise the internal temperature to kill unwanted cells. We use the same principle with infrared saunas. Also, saunas are a great detox. As a tumor shrinks, it sheds a large quantity of debris. Saunas assist the body's efforts to move out the toxins through the sweat. ---Therapeutic doses of vitamin C, administered intravenously, have been proven to defeat cancer cells. The National Institutes of Health confirmed in 2005 that vitamin C is selectively toxic to cancer cells and that tumor-toxic levels of vitamin C can be attained using intravenous administration. ---Poly-MVA, or lipoic acid palladium complex, defeats cancer on an energetic level while helping the liver filter out spent chemo agents from the body. ---We also make use of anti-oxidants like glutathione, various herbs and botanical preparations, coffee enemas, and chelation. Special attention is paid to nourishing the liver, the key organ for that all-important job of detoxification. ---After administering IPT, along with vitamins, herbs, immune enhancers, and chelation, repeat testing 4-6 weeks later will often show that the cancer has regressed, or even disappeared. ###IPT's Positive Impact on Cachexia ---he culprit behind perhaps half the cancer deaths is a wasting syndrome called cachexia (pronounced "ka-kek-see-ah"). Patients lose weight and literally starve to death. ---Because cancer cells need even more energy than regular cells, the cancer cells gobble up the incoming nutrition first. Your healthy cells get what is left over which can mean the rest of your cells starve when conventional treatment leaves you too nauseated to eat. The tumor stays strong, but the patient wastes away. ---The hypoglycemic pulse that occurs with the administration of insulin actually helps the body assimilate the nutrition in food – vitamins, minerals, and enzymes. Because IPT is a gentler approach, patients do not get the severe bouts of nausea so common with conventional chemotherapy due to destruction of the rapidly dividing and always renewed cells lining the intestinal tract. ###The Cellular Genetics Test ---hich chemo drugs shall we use Which complementary therapies are right for you ---Unlike conventional chemotherapy treatment, IPT is not a one-size-fits-all approach. You are unique, and your response to various drugs and complementary therapies is not necessarily the same as the next person's. ---Think back to a time when you had a bladder infection. The lab tested your urine sample against different antibiotics to find out which ones were most effective at killing the bacteria. We use the same concept when choosing therapies for IPT. ---We take a sample of your blood and test it against the chemo drugs and the various complementary therapies to find out what will be most effective for you. We also look at the genetic makeup of your very own cancer. When we custom tailor your therapy, you have a better result. This test is called the BioFocus Analysis. ---The best lab in the world for this test, the one that delivers the most consistent results, is in Germany. The test is not inexpensive, and insurance usually does not pay for this test. But we strongly feel it is the best money you will ever spend. ---The BioFocus Anaylsis shows us the genetic fingerprint of potential metastatic cancer cells, what are called circulating tumor cells. These cells are in the bloodstream; they are the metastatic "seeds" that can break away from the primary site of cancer and spread to other parts of the body. Understanding circulating tumor cells (CTC) is critically important, since it is the spread of cancer to other parts of the body – and not the primary cancer – that is often responsible for the death of a person with cancer. ---Also, metastatic cancer cells can vary genetically from the primary tumor. At least two studies with breast cancer patients have demonstrated that CTC can be HER2 positive while the primary breast tumor can be HER2 negative.[4,5] ---The BioFocus Anaylsis can predict which men with prostate cancer are more or less likely to benefit from surgery by looking at the makeup of their circulating tumor cells.[6] ---A landmark study published in the New England Journal of Medicine in 2007 compared women with lymph node-positive breast cancer who received the standard trio of chemotherapy drugs – Adriamycin¢ç, Cytoxan¢ç, and Taxol¢ç (called ACT) to women who did not receive any chemotherapy. Their HER2 status was also determined – the genetic characteristic of the cancer. Researchers discovered that women who were HER2 negative and estrogen receptor positive did not benefit at all from taking Taxol¢ç.[7] Because approximately two thirds of women with breast cancer fall into this category, the ramifications of this study are immense. So much for the ineffectiveness of the one-size-fits-all approach to cancer. ---A study published in the Journal of the National Cancer Institute in 2008 measured the effectiveness of an anthracycline-based chemotherapy regimen in 5,354 women with early-stage breast cancer. Anthracyclines are a class of chemotherapy drugs of which Adriamycin¢ç is a key member. Scientists determined that women with early-stage breast cancer who were HER2 negative derived absolutely no benefit from taking Adriamycin¢ç or other anthracycline drugs.[8] Given that approximately 80% of breast cancers are HER2 negative, then only 1 out of 5 women with breast cancer can benefit from these drugs that have considerable toxicity associated with their use. In another study, 7% of patients treated with Adriamycin¢ç developed congestive heart failure.[9] ###Frequency of Treatments ---With standard chemotherapy, treatments are often spaced several weeks apart, to allow the body to recover from the harsh effects of the treatment. Since the standard dose chemotherapy attacks all rapidly dividing cells, almost every patient experiences hair loss, and frequently they develop diarrhea and intestinal tract ulcerations as well. Treatment is often limited by the number and severity of the "side effects" which the patient experiences. In addition, the length of time between treatments allows the tumor cells which were not killed initially to continue growing. Sometimes the cells not killed become resistant to the chemotherapeutic agent which was used, and by spacing the treatments so far apart (in order to protect the life of the patient) the resistant population of cells is allowed to take over. ---IPT is a more enlightened paradigm which tailors treatment towards the individual uniqueness of your body and your cancer. With IPT therapy, we generally start with low-dose chemotherapy agents twice a week for the first month. The frequency may then be reduced to once a week, and eventually to once every 2-3 months, until there is no further sign of cancer cells in the blood, and the tumor is no longer visible by conventional means. Chemotherapy agents are interspersed with complementary therapies. So on Monday, for example, you may receive chemotherapy agents and on Wednesday, you may receive intravenous vitamin C. ###How to Begin ---e encourage you to request an orientation so you can make an educated decision. There is no charge for this. Come meet the doctors and staff, and tour the clinic. Meet other patients. The course of action you choose is a significant commitment, and one that will impact those around you. Feel free to bring family to the orientation. Ask every question that is on your mind. ---For your first appointment (after the orientation visit), plan to spend two hours with us. Bring all your medical records and test results. We will ask you to fill out a history form ahead of time so you can do that at home where you have access to information about prior vaccinations, surgeries, mercury fillings and root canals, major emotional traumas you have experienced in life, etc. ---We have an integrative cancer therapy program that provides an approach for the short and the long term – the treatment is tough enough to defeat cancer in the short term, yet leave your body nourished and empowered to ward off cancer on its own in the long term so the cancer does not return. ---"Nothing in life is to be feared. It is only to be understood." - Marie Curie, awarded Nobel Prizes in physics and chemistry ###Frequently Asked Questions About IPT •  Is IPT covered by Medicare The American Standard of Care considers IPT to be an "experimental" therapy, and therefore not "medically necessary," despite the fact that IPT has been in use for more than 70 years, and is used as a standard form of cancer therapy all over Europe. Reimbursement very much depends upon your policy. We use standard drugs and standard coding, so the insurance codes are the same as those used for conventional chemotherapy. Some patients find the drugs are reimbursed, but the insulin and complementary therapies are not. (Apparently, the trick is not to mention the term IPT orally or in writing to the insurance company.) •  How many treatments are needed It depends upon what stage the cancer is in, and how aggressive the cancer is. Basic therapy includes the following: • two treatments per week x 3 weeks • then one treatment per week x 6 weeks • then one treatment every other week x 6 weeks • then one treatment per month x 6 months -----The schedule may be modified, depending on the patient's response to therapy. We may also use nutritional therapies, in addition to the IPT, again depending on the underlying state of health, and how much in the way of conventional chemotherapy or radiation therapy the patient has had before starting IPT. •  Are there any side effects If the patient is very weakened, or already has a compromised immune system from prior chemotherapy, there may be some minor side effects – some drop in white blood cell count, some hair loss, some nausea. However, in a patient whose immune system is not already compromised, there are minimal side effects. Sometimes a patient will complain of fatigue after the treatment. Other than a little fatigue for a day, we have seen no significant side effects to date. •  Is IPT as effective as standard chemotherapy We think it is more effective because IPT does not inflict the severe damage to the immune system that conventional chemo and radiation do; cancer is first and foremost a failure of the immune system. When combined with the chemosensitivity test, we know that we are treating with drugs to which the circulating tumor cells are sensitive, so the effectiveness of treatment is much improved. •  How much does IPT cost The cost very much depends upon your state of health at the time you start the treatments. For someone who has an intact immune system, who does not require daily nutritional IVs in addition to the IPT, the cost is less than for someone who is very ill, with a very compromised immune system, requiring intravenous nutritional therapy and frequent monitoring. Average charge for an IPT treatment is $1200 – $1400 per treatment. If you compare the significant deductable costs of standard chemotherapy, people often find they will be about the same amount of money out of pocket, and you will experience a much better quality of life, without the massive side effects from standard chemotherapy. ###For further information, go to our library and read about cancer. -------------------------------------------------------------------------------- References [1] Morgan G, Ward R et al. The contribution of cytotoxic chemotherapy to 5-year survival in adult malignancies. Clin Oncol (R Coll Radiol). 2004 Dec;16(8):549-60. [2] Scavo LM, Karas et al. Insulin-Like Growth Factor-I Stimulates Both Cell Growth and Lipogenesis during Differentiation of Human Mesenchymal Stem Cells into Adipocytes. J Clin Endocrin Metab 89;7:3542-3552. [3] Litsey T. Acupuncture vs. Cancer: Re-Engaging the Body's Immune System . AcupunctureToday. October, 2003, Vol. 04, Issue 10 [4] S Meng, D Tripathy, et al; HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A. June 22, 2004;101(25):9393-8. [5] P. Wülfing, J Borchard, et al; HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients. Clin Cancer Res. March 15, 2006;12(6):1715-20. [6] CA Olsson, GM De Vries, et al; The use of RT-PCR for prostate-specific antigen assay to predict potential surgical failures before radical prostatectomy: molecular staging of prostate cancer. Br J Urol. March 7, 1996;7(3):411-7. [7] DF Hayes, AD Thor, et al; Cancer and Leukemia Group B (CALGB) Investigators. HER2 and response to paclitaxel in node-positive breast cancer. New England Journal of Medicine, October 11, 2007;357(15):1496-506. [8] A Gennari, MP Sormani ,et al; HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a pooled analysis of randomized trials. J Natl Cancer Inst. January 2, 2008; 100(1):14-20. [9] SM Swain, FS Whaley, MS Ewer; Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. June 1, 2003; 97(11):2869-79. ´ÙÀ½±Û : °øȲÀå¾Ö¶õ ÀÌÀü±Û : ¼ú ¶§¹®¿¡ ÀåÀº ¾î¶±ÇØ~